https://www.biopharmawatch.com/news/RDNT/radnet-presentation-jefferies-conference-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026 https://www.biopharmawatch.com/news/MNOV/medicinova-investor-conferences-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z MediciNova to Participate in Two Investor Conferences in September https://www.biopharmawatch.com/news/GMAB/extraordinary-general-meeting-genmab-october-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z Notice to Convene an Extraordinary General Meeting of Genmab A/S https://www.biopharmawatch.com/news/ROIV/pulmovant-positive-results-phocus-study-mosliciguat BiopharmaWatch en 2026-09-08T10:00:00.000Z Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study https://www.biopharmawatch.com/news/BLTE/belite-bio-submission-new-drug-application-japan BiopharmaWatch en 2026-09-08T10:00:00.000Z Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-valiant-trial-verekitug-asthma BiopharmaWatch en 2026-09-08T07:30:00.000Z Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 https://www.biopharmawatch.com/news/DTC/defence-therapeutics-ceo-shareholder-letter BiopharmaWatch en 2026-09-08T07:15:00.000Z Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders https://www.biopharmawatch.com/news/NVS/novartis-delpacibart-etedesiran-phase-iii-harbor-study-update BiopharmaWatch en 2026-09-08T05:00:00.000Z Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) https://www.biopharmawatch.com/news/BNXT/bionxt-sublingual-everolimus-odf-study BiopharmaWatch en 2026-09-08T03:05:00.000Z BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-slabs-trial-success BiopharmaWatch en 2026-09-08T02:00:00.000Z Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met https://www.biopharmawatch.com/news/NYXH/nyxoah-breathe-study-first-patient-implanted BiopharmaWatch en 2026-09-07T20:05:00.000Z Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System https://www.biopharmawatch.com/news/ASND/ascendis-endocrinology-rare-disease-data-espe-2026 BiopharmaWatch en 2026-09-07T11:00:00.000Z Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-step-young-phase-3-results BiopharmaWatch en 2026-09-07T10:00:00.000Z Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-07 BiopharmaWatch en 2026-09-07T07:15:28.530Z Biotech Catalysts to Watch: Key Developments for September 2026 https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:15:00.000Z Eightco Holdings (NASDAQ: ORBS) gibt einen Gesamtbestand von rund 380 Millionen US-Dollar bekannt, darunter Anteile an OpenAI und Beast Industries sowie mehr als 16.000 ETH und fast 302 Millionen WLD-Token https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:04:00.000Z Eightco Holdings (NASDAQ : ORBS) annonce un actif total d'environ 380 millions de dollars, comprenant notamment OpenAI, Beast Industries, plus de 16 000 jetons ETH et près de 302 millions de jetons WLD https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-appoints-on365-investor-relations-adviser BiopharmaWatch en 2026-09-07T02:00:00.000Z Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser